{"id":"W2838357484","doi":"10.1093/annonc/mdy232","title":"Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study","year":2018,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":367,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pembrolizumab; Response Evaluation Criteria in Solid Tumors; Internal medicine; Prostate cancer; Oncology; Clinical endpoint; Cohort; Adverse effect; Progressive disease; Cancer; Urology; Surgery; Clinical trial; Disease; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002774985,0.0004421835,0.0008714438,0.0001879097,0.0003076665,0.001099794,0.0004864594,0.0005809895,0.002147418],"category_scores_gemma":[0.003519476,0.0003122831,0.0009359336,0.0008023832,0.0003405662,0.0009918195,0.0004782193,0.001408373,0.0003499633],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005239177,"about_ca_system_score_gemma":0.0005770414,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001375439,"about_ca_topic_score_gemma":0.002826323,"domain_scores_codex":[0.9988959,0.0004858338,0.0000899534,0.0001927829,0.0001927579,0.0001427856],"domain_scores_gemma":[0.9975669,0.0007975847,0.0007723504,0.0002959509,0.0002130748,0.000354081],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1649392,0.001818367,0.6844399,0.001484065,0.0128076,0.001318675,0.0003991991,0.00078538,0.01662118,0.00117439,0.008572612,0.1056394],"study_design_scores_gemma":[0.01612708,0.01151911,0.9384387,0.0002017694,0.01143899,0.001556375,0.0004586258,0.0004581304,0.001506775,0.0006111048,0.01763287,0.00005051269],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9841404,0.008166422,0.0001794215,0.001080304,0.0000857031,0.00009242506,0.001441544,0.000007931848,0.004805767],"genre_scores_gemma":[0.9962159,0.001741635,0.0001453117,0.0004200928,0.0001288259,0.00002989836,0.0008103101,0.000005920837,0.0005020888],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002774985,"threshold_uncertainty_score":0.01467568,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06985392706225708,"score_gpt":0.4013476399603873,"score_spread":0.3314937128981302,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}